These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 10469686)

  • 1. Recombinant human follicle stimulating hormone versus human menopausal gonadotrophin induction: effects in mature follicle endocrinology.
    Teissier MP; Chable H; Paulhac S; Aubard Y
    Hum Reprod; 1999 Sep; 14(9):2236-41. PubMed ID: 10469686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of follicle steroidogenesis from normal and polycystic ovaries in women undergoing IVF: relationship between steroid concentrations, follicle size, oocyte quality and fecundability.
    Teissier MP; Chable H; Paulhac S; Aubard Y
    Hum Reprod; 2000 Dec; 15(12):2471-7. PubMed ID: 11098013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human chorionic gonadotrophin and steroid concentrations in follicular fluid: the relationship to oocyte maturity and fertilization rates in stimulated and natural in-vitro fertilization cycles.
    Enien WM; el Sahwy S; Harris CP; Seif MW; Elstein M
    Hum Reprod; 1995 Nov; 10(11):2840-4. PubMed ID: 8747029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of basal luteinizing hormone:follicle-stimulating hormone ratio in the treatment of patients with polycystic ovarian syndrome by assisted reproduction techniques.
    Tarlatzis BC; Grimbizis G; Pournaropoulos F; Bontis J; Lagos S; Spanos E; Mantalenakis S
    Hum Reprod; 1995 Oct; 10(10):2545-9. PubMed ID: 8567767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacokinetic and endocrine comparison of recombinant follicle-stimulating hormone and human menopausal gonadotrophin in polycystic ovary syndrome.
    Balasch J; Fábregues F; Casamitjana R; Peñarrubia J; Vanrell JA
    Reprod Biomed Online; 2003; 6(3):296-301. PubMed ID: 12735863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian responses to recombinant FSH or HMG in normogonadotrophic women following pituitary desensitization by a depot GnRH agonist for assisted reproduction.
    Balasch J; Peñarrubia J; Fábregues F; Vidal E; Casamitjana R; Manau D; Carmona F; Creus M; Vanrell JA
    Reprod Biomed Online; 2003; 7(1):35-42. PubMed ID: 12930572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between prolactin, gonadotrophins and steroid hormones in serum and follicular fluid after stimulation with gonadotrophin-releasing hormone agonists and human menopausal gonadotrophin for an in-vitro fertilization programme.
    Kamel MA; Zabel G; Bernart W; Neulen J; Breckwoldt M
    Hum Reprod; 1994 Oct; 9(10):1803-6. PubMed ID: 7844206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone.
    Balasch J; Miró F; Burzaco I; Casamitjana R; Civico S; Ballescá JL; Puerto B; Vanrell JA
    Hum Reprod; 1995 Jul; 10(7):1678-83. PubMed ID: 8582960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients.
    Smitz J; Andersen AN; Devroey P; Arce JC;
    Hum Reprod; 2007 Mar; 22(3):676-87. PubMed ID: 17110397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).
    Mitchell R; Buckler HM; Matson P; Lieberman B; Burger HG; Hilton B; Horne G; Dyson M; Robertson WR
    Hum Reprod; 1996 May; 11(5):962-7. PubMed ID: 8671371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovulation induction in clomiphene-resistant anovulatory women: differential follicular response to purified urinary follicle-stimulating hormone (FSH) versus purified urinary FSH and luteinizing hormone.
    Hoffman DI; Lobo RA; Campeau JD; Tsai HM; Holmberg EA; Ono T; Frederick JJ; Platt LD; diZerega GS
    J Clin Endocrinol Metab; 1985 May; 60(5):922-7. PubMed ID: 3920235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential step-up and step-down dose regimen: an alternative method for ovulation induction with follicle-stimulating hormone in polycystic ovarian syndrome.
    Hugues JN; Cédrin-Durnerin I; Avril C; Bulwa S; Hervé F; Uzan M
    Hum Reprod; 1996 Dec; 11(12):2581-4. PubMed ID: 9021354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The empty follicle syndrome: a pharmaceutical industry syndrome.
    Zegers-Hochschild F; Fernández E; Mackenna A; Fabres C; Altieri E; Lopez T
    Hum Reprod; 1995 Sep; 10(9):2262-5. PubMed ID: 8530648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone, oestradiol, progesterone and testosterone concentrations in follicular fluid after ovarian stimulation with various regimes for assisted reproduction.
    Tarlatzis BC; Pazaitou K; Bili H; Bontis J; Papadimas J; Lagos S; Spanos E; Mantalenakis S
    Hum Reprod; 1993 Oct; 8(10):1612-6. PubMed ID: 8300815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of dehydroepiandrosterone sulfate synthesis in women with polycystic ovary syndrome by human menopausal gonadotropin but not purified urinary follicle stimulating hormone: a comparative pilot study.
    Turkmen S; Backstrom T; Idil M
    Gynecol Endocrinol; 2004 Aug; 19(2):69-78. PubMed ID: 15624268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type of gonadotropin during controlled ovarian stimulation affects the endocrine profile in follicular fluid and apoptosis rate in cumulus cells.
    Requena A; Cruz M; Agudo D; Pacheco A; García-Velasco JA
    Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():142-6. PubMed ID: 26751823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens.
    Balasch J; Fábregues F; Creus M; Puerto B; Peñarrubia J; Vanrell JA
    Hum Reprod; 2001 Apr; 16(4):652-6. PubMed ID: 11278212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of recombinant human FSH (rhFSH), urinary purified FSH (uFSH), and hMG on small preantral follicles and tertiary follicles from normal adult and androgen-sterilized female mice.
    Liu X; Andoh K; Mizunuma H; Kamijo T; Kikuchi N; Yamada K; Ibuki Y
    Fertil Steril; 2000 Feb; 73(2):372-80. PubMed ID: 10685546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovulation induction with human menopausal gonadotropin compared to human urinary follicle-stimulating hormone results in a significant shift in follicular fluid androgen levels without discernible differences in granulosa-luteal cell function.
    Polan ML; Daniele A; Russell JB; DeCherney AH
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1284-91. PubMed ID: 3097055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.